Indira Pla, Botond L Szabolcs, Petra Nikolett Péter, Zsuzsanna Ujfaludi, Yonghyo Kim, Peter Horvatovich, Aniel Sanchez, Krzysztof Pawlowski, Elisabet Wieslander, Jéssica Guedes, Dorottya Mp Pál, Anna A Ascsillán, Lazaro Hiram Betancourt, István Balázs Németh, Jeovanis Gil, Natália Pinto de Almeida, Beáta Szeitz, Leticia Szadai, Viktória Doma, Nicole Woldmar, Áron Bartha, Zoltan Pahi, Tibor Pankotai, Balázs Győrffy, A Marcell Szasz, Gilberto Domont, Fábio Nogueira, Ho Jeong Kwon, Roger Appelqvist, Sarolta Kárpáti, David Fenyö, Johan Malm, György Marko-Varga, Lajos V Kemény
UNLABELLED: The utilization of PD1 and CTLA4 inhibitors has revolutionized the treatment of malignant melanoma (MM). However, resistance to targeted and immune-checkpoint-based therapies still poses a significant problem. Here we mine large scale MM proteogenomic data integrating it with MM cell line dependency screen, and drug sensitivity data to identify druggable targets and forecast treatment efficacy and resistance. Leveraging protein profiles from established MM subtypes and molecular structures of 82 cancer treatment drugs, we identified nine candidate hub proteins, mTOR, FYN, PIK3CB, EGFR, MAPK3, MAP4K1, MAP2K1, SRC and AKT1, across five distinct MM subtypes...
February 12, 2024: bioRxiv